Multiple sclerosis

Pharmaceutical Journal

Volumn 262, Issue 7045, 1999, Pages 699-701

  Green, Bruce ^a   Mynes, Simon ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BETA INTERFERON; BETA1A INTERFERON; CANNABIS; GLATIRAMER; INTERFERON BETA SERINE; MUSCLE RELAXANT AGENT;

ANXIETY NEUROSIS; BODY POSTURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEPERSONALIZATION; DEPRESSION; DISEASE COURSE; DYSPHORIA; DYSPNEA; EDEMA; EUPHORIA; FATIGUE; FEVER; HALLUCINATION; HEART PALPITATION; HOT FLUSH; HUMAN; HYPOTENSION; IMMUNOPATHOLOGY; INHALATIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; LIFE EXPECTANCY; MULTIPLE SCLEROSIS; MYALGIA; ORAL DRUG ADMINISTRATION; PAIN; PARANOIA; QUALITY OF LIFE; SHORT SURVEY; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; SUICIDAL BEHAVIOR; TACHYCARDIA; THORAX PAIN;

EID: 0033563198     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (20)

1. The IFNB multiple sclerosis study group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis; clinical results of a multicentre, randomised, double-blind, placebo-controlled trial. Neurology 1993;43:655.
2. Jacobs L, Cookfair D, Rudick R, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the multiple sclerosis collaborative research group (MSCRG). Ann Neurol 1996;39:285.
3. PRISMS (prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) study group. Lancet 1998;352:1498.
4. European study group on interferon beta-lb in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-lb in the treatment of secondary progressive multiple sclerosis. Ibid1998;352:1491.
5. Schartz C, Coulthard-Morris L, Cole B, Vollmer T. The quality-of-life effects of interferon beta-lb in multiple sclerosis. An extended Q-TWiST analysis. Arch Neurol 1997;54:1475.
6. World Health Organisation. The first ten years of the World Health Organisation. Geneva: World Health Organisation, 1958.
7. Evidenced-based health care. Bandolier 1998;5(12):1.
8. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak PP et al. Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicentre, double-blind, placebo controlled trial. The copolymer-1 multiple sclerosis study group. Neurology 1995;45:1268.
9. Cohen JA, Grossman RI, Udupa JK et al. Assessment of the efficacy of copolymer-1 in the treatment of MS by quantitative MRI. J Neuroimmunol 1995;Suppl 1:31.
10. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak PP et al. Extended use of glatiramer acetate is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. The copolymer-1 multiple sclerosis study group. Neurology 1998;50:701.
11. Korczyn AD, Nisipeanu P. Safety profile of copolymer-1: analysis of cumulative experience in the United States and Israel. J Neurol 1996;243(4 Suppl 1):S23.
12. Mancardi GL, Sardanelli F, Parodi RC, Melani E, Capello E, Inglese M et al. Effects of copolymer-1 on serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis. Neurology 1998;50:1127.
13. Petro DJ, Ellenberger C Jr. Treatment of human spasticity with delta-9-tetrahydrocannabinol. J Clin Pharmacol 1981;21(8 Suppl):413S.
14. Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987;7:39.
15. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997;38:44.
16. Taylor HG. Analysis of the medicinal use of marijuana and its societal implications. J Am Pharm Assoc (Wash) 1998;38:220.
17. Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino MD. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994;55:324.
18. Volt EA, Schwarzt RH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med 1997;126:791.
19. Hoffman D, Brunneman DK, Gori GB, Wynder EL. On the carcinogenicity of marijuana smoke. Rec Adv Phytochem 1975;9:63.
20. Wu TC, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking marijuana as compared to tobacco. N Engl J Med 1988;318:347.